News Positive Data from Trials of Revumenib in Combination with Standard of Care Agents in Patients with Acute Leukemias By Chris Wack Shares of Syndax Pharmaceuticals jumped 8% to $18 following the release of positive data from… supervisorDecember 11, 2023 Read More